首页> 外文期刊>Expert Opinion on Therapeutic Patents >Recent advances in oxazolidinone antibacterial agent research
【24h】

Recent advances in oxazolidinone antibacterial agent research

机译:恶唑烷酮抗菌剂研究的最新进展

获取原文
获取原文并翻译 | 示例
           

摘要

The oxazolidinone class of antibacterial agents, as exemplified by linezolid (Zyvox~(~R), Pharmacia Corp.), represents the first completely new class of antibacterial agents to achieve regulatory approval in over 30 years. Due to their potent activity against multi-drug resistant Gram-positive bacteria, discovery research in this area has flourished, with many pharmaceutical companies worldwide beginning research programmes. With the expanded research efforts, new understanding of the oxazolidinone structure-activity relationship has led to an increased spectrum of activity to include the fastidious Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis. In addition, a deeper understanding of the toxicology, mechanism of action, and mechanism of resistance has emerged.
机译:以利奈唑胺为例的恶唑烷酮类抗菌剂(美国药典公司(Pharmacia Corp.))代表了30年来首个获得监管批准的全新抗菌剂。由于它们对多种药物耐药的革兰氏阳性细菌具有有效的活性,因此该领域的发现研究蓬勃发展,全球许多制药公司都开始研究计划。随着研究工作的扩展,对恶唑烷酮结构-活性关系的新认识导致活性谱增加,包括革兰氏阴性病原体流感嗜血杆菌和卡他莫拉菌。另外,已经出现了对毒理学,作用机理和耐药机理的更深入的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号